Bayer is gearing up to spin off its plastics unit and become a life-sciences-focused company, and as part of that prep, it's going on an investor roadshow to seek feedback on its plans.
Social media success in consumer marketing has advanced beyond counting fans and followers. Today it's all about shares, retweets and links that indicate real consumer engagement with brands....
It may be too little too late. But now the FDA has signed off on the use of transvaginal ultrasound as a means of ensuring the proper placement of the Essure permanent birth control device within three months of its insertion.
Bayer has said it can pump an extra $400 million in revenue out of the OTC portfolio it acquired from Merck last year. And with that target in mind, new launches are on the agenda.
Bayer and Johnson & Johnson know that right now, there's an impression out there that rival drug Eliquis--from Pfizer and Bristol-Myers Squibb--is superior to their next-gen clot-fighter Xarelto, despite their drug's market-share lead.
Whether animal health leader Zoetis receives any more buyout offers after Valeant's reported approach remains to be seen. But if it does, Bayer's leaders insist a competing bid won't be coming from them.
For a while now, Bayer and Johnson & Johnson's Xarelto has had no problem besting its competition, zooming to the lead in the new-age anticoagulant market, despite entering second. Now, though, the notion that rival Eliquis is a superior med is permeating the field, and it's up to the companies to quash that idea if they want to keep their hold on the No. 1 spot.
Japan's Pharmaceuticals and Medical Devices Agency approved Bayer's Eylea for the treatment of diabetes-related visual impairment, the company said in a release June 26.
The U.S. Food and Drug Administration has further formalized its ongoing review of the controversial Essure permanent birth control implant from Bayer.
Bayer is gearing up to spend more than ever before on R&D this year, CEO Marijn Dekkers said, investing in innovation with hopes of pushing some promising therapies onto the market.